- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Epix reports gains and losses after Schering partnership
Schering of Germany’s recent partnership with Epix Medical has paid off in revenue for the small research-based Massachusetts company, but not enough to prevent a dramatic loss, according to Epix’s second-quarter financial earnings.Epix is in
Schering of Germanys recent partnership with Epix Medical has paid off in revenue for the small research-based Massachusetts company, but not enough to prevent a dramatic loss, according to Epixs second-quarter financial earnings.
Epix is in phase III clinical trials for MS-325, an MR contrast agent. As a development-stage company, Epix has no commercial products. Epix, Mallinckrodt, and Schering, whose American counterpart is Berlex, jointly announced a series of agreements covering Epixs MS-325, which was formerly licensed by Mallinckrodt as AngioMark. Epix expects to complete patient trial enrollment for the agent in the first half of 2001 (SCAN 6/21/00).
Epixs net loss for the second quarter (ending June 30) was $4.6 million, as compared to a net loss of $4 million for the second quarter of 1999. Second-quarter revenue was $2.3 million, compared to $267,000 for the same period in 1999, primarily due to development funding by Schering in the second quarter. Total operating expenses for second-quarter 2000 were $6.9 million as compared to $4.5 million for the second quarter of 1999. Research and development expenses increased $2 million during the second quarter of 2000, due to the Schering agreement and clinical trial expenses.
In the same month that it announced these dramatic losses, Epix filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for the issuance of up to three million shares of common stock. Once registered, these shares will be available for sale by the company when it believes market conditions are favorable and investment opportunities are available.
Epix president and CEO Michael Webb said his company has significant funds available for the development of MS-325 and its thrombus-imaging research program. But acquiring more capital through the new stock issuance would allow Epix to accelerate and expand its development if demand warrants, he said.
In other Epix news, the company has promoted Pamela E. Carey to the positions of vice president of finance and administration and chief financial officer. Prior to the promotion, Carey was Epixs treasurer and director of finance.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
